Attenuated transcriptional response to pro-inflammatory cytokines in schizophrenia hiPSC-derived neural progenitor cells.
Cytokine
Differential gene expression
IFNγ
IL-1β
Inflammation
Maternal immune activation
Neurodevelopment
Neurotransmission
Prenatal development
Journal
Brain, behavior, and immunity
ISSN: 1090-2139
Titre abrégé: Brain Behav Immun
Pays: Netherlands
ID NLM: 8800478
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
10
01
2022
revised:
29
05
2022
accepted:
13
06
2022
pubmed:
19
6
2022
medline:
1
9
2022
entrez:
18
6
2022
Statut:
ppublish
Résumé
Maternal immune activation (MIA) during prenatal development is an environmental risk factor for psychiatric disorders including schizophrenia (SZ). Converging lines of evidence from human and animal model studies suggest that elevated cytokine levels in the maternal and fetal compartments are an important indication of the mechanisms driving this association. However, there is variability in susceptibility to the psychiatric risk conferred by MIA, likely influenced by genetic factors. How MIA interacts with a genetic profile susceptible to SZ is challenging to test in animal models. To address this gap, we examined whether differential gene expression responses occur in forebrain-lineage neural progenitor cells (NPCs) derived from human induced pluripotent stem cells (hiPSC) generated from three individuals with a diagnosis of schizophrenia and three healthy controls. Following acute (24 h) treatment with either interferon-gamma (IFNγ; 25 ng/μl) or interleukin (IL)-1β (10 ng/μl), we identified, by RNA sequencing, 3380 differentially expressed genes (DEGs) in the IFNγ-treated control lines (compared to untreated controls), and 1980 DEGs in IFNγ-treated SZ lines (compared to untreated SZ lines). Out of 4137 genes that responded significantly to IFNγ across all lines, 1223 were common to both SZ and control lines. The 2914 genes that appeared to respond differentially to IFNγ treatment in SZ lines were subjected to a further test of significance (multiple testing correction applied to the interaction effect between IFNγ treatment and SZ diagnosis), yielding 359 genes that passed the significance threshold. There were no differentially expressed genes in the IL-1β-treatment conditions after Benjamini-Hochberg correction. Gene set enrichment analysis however showed that IL-1β impacts immune function and neuronal differentiation. Overall, our data suggest that a) SZ NPCs show an attenuated transcriptional response to IFNγ treatment compared to controls; b) Due to low IL-1β receptor expression in NPCs, NPC cultures appear to be less responsive to IL-1β than IFNγ; and c) the genes differentially regulated in SZ lines - in the face of a cytokine challenge - are primarily associated with mitochondrial, "loss-of-function", pre- and post-synaptic gene sets. Our findings particularly highlight the role of early synaptic development in the association between maternal immune activation and schizophrenia risk.
Identifiants
pubmed: 35716830
pii: S0889-1591(22)00162-3
doi: 10.1016/j.bbi.2022.06.010
pmc: PMC9810540
pii:
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
82-97Subventions
Organisme : Medical Research Council
ID : MR/L021064/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/N026063/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Références
Dis Model Mech. 2012 Jan;5(1):26-32
pubmed: 21954066
Mol Psychiatry. 2016 Dec;21(12):1696-1709
pubmed: 26903267
Front Immunol. 2020 Jan 24;10:3139
pubmed: 32117203
Schizophr Res. 2016 Oct;176(2-3):83-94
pubmed: 27450778
Genome Biol. 2010;11(3):R25
pubmed: 20196867
Neurosci Biobehav Rev. 2014 Jan;38:72-93
pubmed: 24247023
J Neurochem. 2012 Mar;120(6):964-73
pubmed: 22192001
J Psychiatr Res. 1999 Nov-Dec;33(6):543-8
pubmed: 10628531
Nat Neurosci. 2020 Nov;23(11):1352-1364
pubmed: 33097921
BMC Bioinformatics. 2016 Nov 25;17(1):483
pubmed: 27884101
Schizophr Bull. 2008 Nov;34(6):1066-82
pubmed: 18791076
Brain Behav Immun. 2013 Jul;31:54-68
pubmed: 22841693
World Health Stat Q. 1988;41(1):32-6
pubmed: 3376487
Neuron. 2011 Dec 22;72(6):951-63
pubmed: 22196331
Mol Psychiatry. 2021 Feb;26(2):396-410
pubmed: 33230204
Biol Psychiatry. 2019 Aug 15;86(4):265-273
pubmed: 31230729
Lancet Psychiatry. 2020 Mar;7(3):254-261
pubmed: 32035031
PLoS Comput Biol. 2015 Apr 17;11(4):e1004219
pubmed: 25885710
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Trends Neurosci. 2019 Nov;42(11):793-806
pubmed: 31493924
Nat Methods. 2011 Apr;8(4):315-7
pubmed: 21378979
Stem Cell Res. 2012 Jan;8(1):134-40
pubmed: 22099027
Arch Gen Psychiatry. 1991 Aug;48(8):764-70
pubmed: 1883262
Immunity. 2022 May 10;55(5):879-894.e6
pubmed: 35443157
Development. 2009 Jul;136(14):2311-22
pubmed: 19542351
Cell. 2006 Aug 25;126(4):663-76
pubmed: 16904174
Mol Psychiatry. 2018 Mar;23(3):735-746
pubmed: 28948968
J Transl Med. 2019 Jul 15;17(1):223
pubmed: 31307492
Schizophr Bull. 2006 Apr;32(2):200-2
pubmed: 16469941
J Clin Invest. 1990 Mar;85(3):943-9
pubmed: 2107212
Nature. 2022 Apr;604(7906):502-508
pubmed: 35396580
J Neuroinflammation. 2012 Apr 30;9:83
pubmed: 22546005
Front Psychiatry. 2020 Feb 26;11:72
pubmed: 32174851
Nat Rev Neurosci. 2020 Mar;21(3):139-152
pubmed: 32042145
Neuron. 2009 Oct 15;64(1):40-5
pubmed: 19840547
Brain Behav Immun. 2020 Jul;87:634-644
pubmed: 32109548
Neuron. 2015 Jun 3;86(5):1203-14
pubmed: 26050040
Neuropsychopharmacology. 2004 Jul;29(7):1221-9
pubmed: 15085088
Bioinformatics. 2021 Apr 19;37(2):192-201
pubmed: 32730587
J Transl Med. 2018 Nov 7;16(1):304
pubmed: 30404629
Nat Protoc. 2010 Feb;5(2):371-82
pubmed: 20134422
Nat Neurosci. 2019 Mar;22(3):374-385
pubmed: 30718903
Mol Cell Neurosci. 2020 Mar;103:103463
pubmed: 31917333
Mol Brain. 2021 Jun 26;14(1):98
pubmed: 34174924
Sci Rep. 2019 Nov 15;9(1):16928
pubmed: 31729416
Nat Biotechnol. 2011 Mar;29(3):279-86
pubmed: 21293464
Nature. 2016 Feb 11;530(7589):177-83
pubmed: 26814963
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Eur Respir J. 2017 Jun 15;49(6):
pubmed: 28619954
Neurosci Biobehav Rev. 2015 Jan;48:10-21
pubmed: 25446950
Genome Biol. 2014 Feb 03;15(2):R29
pubmed: 24485249
Science. 2016 Aug 19;353(6301):772-7
pubmed: 27540164
J Neuroinflammation. 2018 May 26;15(1):165
pubmed: 29803226
Nat Genet. 2018 Mar;50(3):381-389
pubmed: 29483656
Biol Psychiatry. 2021 Mar 1;89(5):486-496
pubmed: 32826066
Brain Behav Immun. 2020 Nov;90:196-207
pubmed: 32798663
Schizophr Res. 2007 Dec;97(1-3):51-9
pubmed: 17764905
Sci Adv. 2020 Aug 19;6(34):eaay9506
pubmed: 32875100
Nat Commun. 2017 Dec 20;8(1):2225
pubmed: 29263384
Am J Psychiatry. 2019 Jun 1;176(6):477-486
pubmed: 30922102
Immunol Rev. 2010 Jul;236:219-42
pubmed: 20636820
Front Neuroanat. 2018 Dec 06;12:104
pubmed: 30574073
Arch Gen Psychiatry. 2004 Aug;61(8):774-80
pubmed: 15289276
J Immunol. 2017 Jul 15;199(2):383-388
pubmed: 28696328
Front Psychiatry. 2013 May 30;4:47
pubmed: 23750138
Science. 2018 Dec 14;362(6420):
pubmed: 30545856
Mol Psychiatry. 2015 Mar;20(3):361-8
pubmed: 24686136
Cell Rep. 2021 Mar 16;34(11):108868
pubmed: 33730571
Stem Cells Int. 2012;2012:738910
pubmed: 22550517
J Neuroimmunol. 2005 Feb;159(1-2):106-12
pubmed: 15652408
Front Immunol. 2020 Jun 09;11:1145
pubmed: 32582210
Nat Methods. 2017 Feb;14(2):135-139
pubmed: 27941783
Cell. 2021 Jan 7;184(1):149-168.e17
pubmed: 33278357
Schizophr Bull. 2018 Jun 6;44(4):865-875
pubmed: 28981869
Psychopharmacology (Berl). 2014 Mar;231(6):1079-88
pubmed: 23839283
Philos Trans R Soc Lond B Biol Sci. 2018 Mar 19;373(1742):
pubmed: 29352031
Nat Biotechnol. 2007 Jul;25(7):803-16
pubmed: 17572666
Hum Mol Genet. 2020 Jan 1;29(1):159-167
pubmed: 31691811
Brain Behav Immun. 2020 Aug;88:619-630
pubmed: 32335198